Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.1.149 - Platelet-activating factor acetyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction.
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Aggressive Periodontitis
Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis.
Alzheimer Disease
Intracellular PAF-Acetylhydrolase Type I.
Anaphylaxis
Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study.
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Angina, Stable
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Platelet-activating factor acetylhydrolase activity in patients with chronic stable angina (preliminary results).
Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty.
The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina.
Angina, Unstable
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Aortic Valve Stenosis
Role of serum high density lipoprotein levels and functions in calcific aortic valve stenosis progression.
Asthma
Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses.
Massage Therapy in Children with Asthma: A Systematic Review and Meta-Analysis.
Plasma PAF-acetylhydrolase: an unfulfilled promise?
Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
Atherosclerosis
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).
Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Development of a seaweed derived platelet activating factor acetylhydrolase (PAF-AH) inhibitory hydrolysate, synthesis of inhibitory peptides and assessment of their toxicity using the Zebrafish larvae assay.
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study.
Generation of reactive oxygen species and activity of platelet-activating factor acetylhydrolase in human monocyte-derived macrophages.
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice.
Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Plasma PAF-acetylhydrolase: an unfulfilled promise?
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery.
Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals.
Breast Neoplasms
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers.
Carcinoma
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Carcinoma, Renal Cell
The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase.
Cardiomyopathy, Hypertrophic
Association of a G994 --> T (Val279 --> Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy.
Cardiovascular Diseases
Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.
Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.
Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.
Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.
Carotid Artery Diseases
Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals.
Cholestasis
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Chronic Periodontitis
Activity of platelet activating factor acetylhydrolase following phase I periodontal therapy.
Chronic Urticaria
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Classical Lissencephalies and Subcortical Band Heterotopias
Intracellular PAF-Acetylhydrolase Type I.
The functional implications of the dimerization of the catalytic subunits of the mammalian brain platelet-activating factor acetylhydrolase (Ib).
Coinfection
Expression and DNA microarray analysis of a platelet activating factor-related molecule in severe pneumonia in mice due to influenza virus and bacterial co-infection.
Colitis, Ulcerative
Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease.
Platelet-activating factor acetylhydrolases in Caco-2 cells and epithelium of normal and ulcerative colitis patients.
Colonic Neoplasms
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Coronary Artery Disease
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease.
Coronary Disease
Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.
Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia.
Platelet-activating factor acetylhydrolase activity in patients with chronic stable angina (preliminary results).
Crohn Disease
Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease.
Diabetes Mellitus
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
Diabetes Mellitus, Type 1
Characterization of PAF-AH Ib1 in NOD mice: PAF-AH may not be a candidate gene of the diabetes susceptibility Idd4.1 locus.
Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy.
Diabetes Mellitus, Type 2
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
Digestive System Diseases
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Dyslipidemias
Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration.
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
Enterocolitis, Necrotizing
Presence of platelet-activating factor-acetylhydrolase in milk.
Essential Hypertension
Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.
Fetal Growth Retardation
Increased platelet-activating factor-acetylhydrolase activity in the umbilical venous plasma of growth-restricted fetuses.
Glomerulonephritis, IGA
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy.
Heart Diseases
Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS.
Hepatitis
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Hepatitis B
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
HIV Infections
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Hypercholesterolemia
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
Studies on HDL associated enzymes under experimental hypercholesterolemia: possible modulation on selenium supplementation.
Hyperlipidemias
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina.
Hypertension
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
Platelet-activating factor-acetylhydrolase activity in normotensive and hypertensive pregnancies.
Hypertension, Pregnancy-Induced
Platelet-activating factor-acetylhydrolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies.
Hypothyroidism
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
Infections
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
Leishmania parasites possess a platelet-activating factor acetylhydrolase important for virulence.
Lipid mediators and vector infection: Trypanosoma rangeli inhibits Rhodnius prolixus hemocyte phagocytosis by modulation of phospholipase A2 and PAF-acetylhydrolase activities.
Lipoprotein lipase and hydrofluoric acid deactivate both bacterial lipoproteins and lipoteichoic acids, but platelet-activating factor-acetylhydrolase degrades only lipoteichoic acids.
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Insulin Resistance
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
Intracranial Thrombosis
Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis.
Ischemic Attack, Transient
Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia.
Ischemic Stroke
Associations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke.
Kidney Failure, Chronic
Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Lecithin Cholesterol Acyltransferase Deficiency
Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
Leptospirosis
Serum activity of platelet-activating factor acetylhydrolase is a potential clinical marker for leptospirosis pulmonary hemorrhage.
Serum platelet-activating factor acetylhydrolase and paraoxonase-1 activity in horses infected with Leptospira spp.
Liver Cirrhosis
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Liver Diseases
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Lung Diseases
Lung endothelial cell platelet-activating factor production and inflammatory cell adherence are increased in response to cigarette smoke component exposure.
Lupus Erythematosus, Systemic
Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.
Macular Degeneration
Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models.
Melanoma
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
Meningitis
Detection and characterization of 45 kDa platelet activating factor acetylhydrolase in cerebrospinal fluid of children with meningitis.
Migraine Disorders
Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks.
Multiple Sclerosis
Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis.
Myocardial Infarction
Anti-ischemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor.
Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
Myoma
Platelet-activating factor acetylhydrolase isoforms I and II in human uterus. Comparisons with pregnant uterus and myoma.
Neoplasms
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response.
Intracellular PAF-Acetylhydrolase Type I.
Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Platelet-activating factor acetylhydrolase inhibits alveolar macrophage activation in vivo.
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
Platelet-activating factor-acetylhydrolase can monodeacylate and inactivate lipoteichoic Acid.
Non-ST Elevated Myocardial Infarction
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Obstetric Labor, Premature
Smoking and preterm labor: effect of a cigarette smoke extract on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages.
Otitis Media
The presence of platelet-activating factor-acetylhydrolase in human middle ear effusions.
Otitis Media with Effusion
The presence of platelet-activating factor-acetylhydrolase in human middle ear effusions.
Ovarian Neoplasms
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Peanut Hypersensitivity
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Peritonitis
Platelet-activating factor acetylhydrolase inhibits alveolar macrophage activation in vivo.
platelet-activating factor acetyltransferase deficiency
Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis.
Pneumonia
Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time depended role of phospholipases A(2).
Lipoxin A4 and Platelet Activating Factor Are Involved in E. coli or LPS-Induced Lung Inflammation in CFTR-Deficient Mice.
Lung production of platelet-activating factor acetylhydrolase in oleic acid-induced acute lung injury.
Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
Polycystic Ovary Syndrome
Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS.
Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.
Pre-Eclampsia
Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study.
Maternal and fetal plasma platelet-activating factor-acetylhydrolase activity and distribution in pre-eclampsia.
Primary Ovarian Insufficiency
Platelet-activating factor acetylhydrolase and premature ovarian failure.
Prostatic Neoplasms
Comparison of serum acetyl hydrolase (PAF-AH) and paraoxonase 1 (PON1) values between prostate cancer patients and a control group.
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Proteinuria
Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins.
Psoriasis
Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation.
Renal Insufficiency, Chronic
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.
Respiratory Distress Syndrome
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
The macrophage response to endotoxin requires platelet activating factor.
Sarcoma, Kaposi
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
Seizures
Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Sepsis
Bacterial Clearance Is Improved in Septic Mice by Platelet-Activating Factor-Acetylhydrolase (PAF-AH) Administration.
Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.
Plasma PAF-acetylhydrolase: an unfulfilled promise?
Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Severe Combined Immunodeficiency
The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase.
Spasm
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm.
Starvation
Biological role of Trichoderma harzianum-derived platelet-activating factor acetylhydrolase (PAF-AH) on stress response and antagonism.
Stroke
Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Thrombosis
Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.
Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits.
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Triple Negative Breast Neoplasms
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Urticaria
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Vascular Diseases
Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.